Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities: 2019-2024

Historic Other Non-Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $410,000.

  • 4D Molecular Therapeutics' Other Non-Current Liabilities fell 12.88% to $345,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $345,000, marking a year-over-year decrease of 12.88%. This contributed to the annual value of $410,000 for FY2024, which is 11.11% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Other Non-Current Liabilities stood at $410,000 for FY2024, which was up 11.11% from $369,000 recorded in FY2023.
  • 4D Molecular Therapeutics' Other Non-Current Liabilities' 5-year high stood at $1.9 million during FY2020, with a 5-year trough of $212,000 in FY2022.
  • Over the past 3 years, 4D Molecular Therapeutics' median Other Non-Current Liabilities value was $369,000 (recorded in 2023), while the average stood at $330,333.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first slumped by 88.44% in 2021, then soared by 74.06% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Other Non-Current Liabilities (Yearly) stood at $1.9 million in 2020, then crashed by 88.44% to $214,000 in 2021, then fell by 0.93% to $212,000 in 2022, then soared by 74.06% to $369,000 in 2023, then increased by 11.11% to $410,000 in 2024.